drugset / Trial / NCT03887065
Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a novel, small human peptide designated as JM-4. The study will involve treatment for 5-7 days with JM-4 to determine the effects of Gadolinium(+) lesion number and volume in the brains of patients.
Timeline
- Start
- 2019-06-15
- Primary completion
- 2019-12-15
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JM-4 | Peptide | 1 mg/kg | Intravenous |
| Subject | JM-4 | Peptide | 4 mg/kg | Intravenous |
| Subject | JM-4 | Peptide | 9 mg/kg | Intravenous |